{"nctId":"NCT04079452","briefTitle":"Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals","startDateStruct":{"date":"2020-02-18","type":"ACTUAL"},"conditions":["HIV-1-infection"],"count":15,"armGroups":[{"label":"Doravirine + Descovy® TAF/FTC","type":"EXPERIMENTAL","interventionNames":["Drug: Doravirine","Drug: Descovy"]}],"interventions":[{"name":"Doravirine","otherNames":["MK-1439"]},{"name":"Descovy","otherNames":["TAF/FTC"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Asymptomatic, HIV-1 infected individuals ≥ 18 years of age\n2. Be on a stable ART continously or ≥3 consecutive months preceding the screening visit. Patients already receiving TAF/FTC+DoravirineC for at least three consecutive months will be eligible.\n3. Plasma HIV-1 RNA at screening \\<40 copies/mL for at least 3 months at the Screening visit.\n4. Signed and dated written informed consent prior to inclusion.\n5. Subjects must agree to utilize a highly effective method of contraception during heterosexual intercourse from the screening visit throughout the duration of the study.\n\nExclusion Criteria:\n\n1. Severe hepatic impairment (Child-Pugh Class C)\n2. Ongoing malignancy\n3. Active opportunistic infection\n4. Primary resistance to any of the ARV included in the study or history of virologic failure with risk of resistance selection to any of the study drugs.\n5. Any verified Grade 4 laboratory abnormality\n6. ALT or AST ≥ 3xULN and/or bilirubin ≥ 1.5xULN\n7. Adequate renal function: Estimated glomerular filtration rate ≥ 50 mL/min\n8. Females who are pregnant (as confirmed by positive serum pregnancy test) or breastfeeding.\n9. Current treatment with antiaggregant or anticoagulant therapy.\n10. History of any neurologic disease/condition/treatment may alter the blood brain barrier permeability.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Total Doravirine Concentrations in Cerebrospinal Fluid","description":"Total Doravirine concentrations in cerebrospinal fluid in HIV-1 infected individual receiving ART with Doravirine+FTC/TAF","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Total Doravirine Concentrations in Blood Plasma","description":"Total Doravirine concentrations in blood plasma","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"417.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Total Doravirine Concentration CSF/Plasma Ratio","description":"total Doravirine CSF/plasma ratio","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":null}]}]}]},{"type":"PRIMARY","title":"HIV-1 RNA in Cerebrospinal Fluid","description":"Number of patients with HIV-1 RNA cerebrospinal fluid \\<40 copies/ml","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]}]},{"type":"PRIMARY","title":"HIV-1 RNA in Blood Plasma","description":"Number of patients with HIV-1 RNA in blood plasma \\<40 copies/ml","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]}]},{"type":"PRIMARY","title":"Unbound Doravirine Concentrations in CSF","description":"Unbound Doravirine concentrations in cerebrospinal fluid in HIV-1 infected individual receiving ART with Doravirine+FTC/TAF","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Doravirine Concentrations in Blood Plasma","description":"Unbound Doravirine concentrations in blood plasma","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Unbound Doravirine Concentration CSF/Plasma Ratio","description":"Unbound Doravirine CSF/plasma ratio","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":["Diarrhea","Thoracic pain"]}}}